The national map below displays public locations that have received shipments of U.S. Government-procured COVID-19 therapeutics under U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) authority. The long-acting antibody combination, Evusheld; the monoclonal antibody treatment, bebtelovimab; as well as the oral antiviral therapies Lagevrio (molnupiravir), Paxlovid, and Renal Paxlovid are products authorized by the FDA for either prevention (Evusheld) or treatment (bebtelovimab, Lagevrio (molnupiravir), Paxlovid, and Renal Paxlovid) of COVID-19.
Sotrovimab distribution was paused due to the majority prevalence of the BA.2 omicron subvariant on March 25, 2022 following FDA's revised EUA limiting its use.
As of January 24, 2022, allocations of bamlanivimab/etesevimab and REGEN-COV have been paused following FDA’s revised EUA’s for both products limiting their use due to the omicron variant.
These therapies require a prescription by a licensed and authorized provider. The therapeutics locator is intended for provider use. Patients should not contact locations directly unless instructed to do so by their healthcare provider.
Additional resources and information related to COVID-19 Therapeutics currently distributed by the federal government can be found on the ASPR COVID-19 Therapeutics page. For questions regarding this site, contact 1-800-232-0233 (TTY 888-720-7489).
Search by therapy and by zip code to find potential locations.